Background/Aims: Emerging evidence suggests that the propagation of oral squamous cell carcinoma (OSCC) is influenced by the abnormal expression of microRNAs (miRNAs). This study aimed to characterize the involvement of miR-182-5p in OSCC by targeting the calcium/ calmodulin-dependent protein kinase II inhibitor CAMK2N1. Methods: miR-182-5p expression was quantified in OSCC tissues and cell lines with reverse transcription polymerase chain reaction (RT-PCR). Cell colony formation, Cell Counting Kit-8 (CCK-8), Ki-67, and nude mouse xenograft assays were used to characterize the role of miR-182-5p in the proliferation of OSCC. A miR-182-5p target gene was identified with western blotting, RT-PCR, and luciferase activity assays. OSCC patient survival based on CAMK2N1 expression was also analyzed. Results: miR-182-5p was up-regulated in in vitro cell lines and in vivo clinical OSCC samples. CCK-8, colony formation, and Ki-67 assays revealed that miR-182-5p promoted the growth and proliferation of OSCC cells. miR-182-5p directly targeted CAMK2N1, as evidenced by luciferase assays and target prediction algorithms. CAMK2N1 operated as a tumor suppressor gene in patients with OSCC. Down-regulating miR-182-5p expression in the CAL-27 cell line restored CAMK2N1-mediated OSCC cell proliferation. miR-182-5p expression inhibited the activation of AKT, ERK1/2, and NF-κB. Mice injected with CAL-27 cells transfected with miR-182-5p-inhibitor demonstrated a significant increase in tumor size and weight and increased CAMK2N1 mRNA and protein expression compared with the miR-negative control group. Conclusion: The miR-182-5p-CAMK2N1 pathway can be potentially targeted to regulate the proliferation of OSCC cells.
Introduction
Oral squamous cell carcinoma (OSCC) represents over 90% of oral cavity cancers [1, 2] , with a rapidly increasing incidence among young and middle-aged individuals due to excessive smoking and alcohol consumption [3] . Despite efforts to improve its early diagnosis and treatment, advanced OSCC still has an extremely poor 5-year survival rate of less than 63%, mainly due to high recurrence rates brought about by its ability to invade local tissues and to metastasize [4] . Surgery remains the first-line treatment for a significant proportion of patients with OSCC [5] . However, surgical treatment may require partial tongue removal, leaving patients with severe oral dysfunction resulting in dysphagia and dysarthria. Hence, the quality of life of patients receiving surgery is low. More methods that enable its early diagnosis and treatment are much needed in OSCC. Studies have found that some cancer genes and tumor suppressor genes may be crucial in enhancing or initiating the development of OSCC. Nevertheless, the specific molecular pathways underlying the development of OSCC are still unclear [6] [7] [8] . Therefore, it is important to elucidate the genomic and epigenomic mechanisms participating in multistep carcinogenesis and the progression of OSCC.
A myriad of cellular processes, including differentiation, development, proliferation, and apoptosis, are dictated by microRNAs (miRNAs), which are small segments of non-coding RNAs [9, 10] . By negatively regulating gene expression at the post-transcriptional level, these single-stranded RNAs can inhibit gene translation and trigger the direct degradation of target messenger RNAs (mRNAs) [11] . More than one-third of protein-coding genes are estimated to be under miRNA translational control, with a single miRNA able to regulate hundreds of protein-coding genes [12, 13] .
miR-182-5p is a highly conserved miRNA whose expression has been found to be increased in several malignant human cancers, such as glioblastoma, hepatocellular carcinoma, and breast and gastric cancer [14] . However, how miR-182-5p contributes to the proliferation of OSCC cells remains poorly characterized. We aimed to investigate how miR-182-5p functions in the pathophysiology of OSCC, specifically with regard to its ability to enhance proliferation.
Materials and Methods

Human-derived OSCC tumor samples
Twenty human-derived OSCC tumor specimens complete with surrounding non-cancerous tissue were sampled between 2015 to 2017 at the First Affiliated Hospital of Harbin Medical University (Harbin, China). All tissues were taken prior to the initiation of radiotherapy or chemotherapy and were frozen immediately and store at −80°C until required. Cytological and/or pathological evidence of OSCC diagnosis was available for each subject. Each patient provided written informed consent.
Cell line culture
Human normal oral epithelial keratinocytes (hNOK) along with OSCC cell lines of human origin (Tca8113, CAL-27, SCC-4, UM-1, and OSC-4) were procured from the Chinese Academy of Science Shanghai Cell Bank (Shanghai, China). All cells were cultured in RPMI 1640 medium or Dulbecco's modified Eagle's medium (HyClone Laboratories, Inc., Logan, UT), both supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA), 100 U/mL penicillin, and 100 μg/mL streptomycin in a humidified chamber of 5% CO 2 at 37°C.
miRNA and transfection protocol miR-182-5p-mimic, miR-182-5p-negative control (miR-NC), miR-182-5p-inhibitor, and CAMK2N1 expression vector were all purchased from Genechem (Shanghai, China). Lipofectamine® 2000 Transfection Reagent (Life Technologies, Gaithersburg, MD) was utilized for the transfection of all cells with the aforementioned miRNAs, following the manufacturer's protocol. RNA extraction and quantitative real-time PCR TRIzol (Invitrogen) was used to extract total RNA according to the manufacturer's instructions. The expression levels of miR-182-5p were quantified with an miRNA-specific TaqMan MiRNA Assay Kit (Applied Biosystems, Foster City, CA). The results were normalized against the expression of U6 small nuclear RNA, with resultant data expressed as Log2-fold changes in relation to miR/U6 levels. miR-182-5p and U6 primers were designed by and purchased from RiboBio Co., Ltd. (Guangzhou, China). CAMK2N1 primer sequences were designed following the procedures described in Hafner et al. [15] .
Western blot analysis
Protease inhibitors (Roche, Indianapolis, IN) in combination with mammalian protein (60-80 μg) extraction reagent (Pierce, Rockford, IL) were utilized to extract protein from cell lysates and cancer tissues. Cell lysates were centrifuged at 13, 000 rpm for 15 min at 4°C. The protein concentration of each sample was measured using the BCA Protein Assay Kit (Pierce). Protein samples were separated in 10-12% sodium dodecyl sulfate-polyacrylamide gels and transferred to nitrocellulose membranes (Pall Corporation, Port Washington, NY). Blocking buffer (5% non-fat milk in phosphate-buffered saline) was used to block the membranes. All membranes were incubated for 1 h with a buffer at room temperature. Primary antibodies
No. 5741S), and anti-β-actin (Cat. No. 4967S) (all obtained from Cell Signaling Technology, Danvers, MA). These antibodies were diluted to 1:500 to 1:1000, incubated overnight with the membranes at 4°C, and subsequently rinsed using Tris-buffered saline with Tween 20. The next day, the membranes were incubated with 1:1000 dilutions of mouse or rabbit secondary antibodies (Cell Signaling Technology). An imaging system (LI-COR Biosciences, Lincoln, NE) was used to produce blot images, while band densities were analyzed with Odyssey 3.0 software using β-actin as the standard.
Cell viability assay
A Cell Counting Kit-8 (CCK-8) assay (Beyotime Institute of Biotechnology, Beijing, China) was utilized to assess CAL-27 cell viability according to the manufacturer's protocols. Briefly, transfected CAL-27 cells were transferred to 96-well plates (3000 cells/well). After incubation for 2 h in 10 μL CCK-8, the absorbance in each well was evaluated at 450 nm (Tecan Infinite M200 Micro Plate Reader; LabX, Männedorf, Switzerland). All experiments were repeated at least three times.
Colony formation assay
The cells were seeded in 60-mm dishes (800 cells/dish) and grown for 10 days. The culture medium was replenished after the 5 th day. The generated cells were methanol-fixed and stained for 10 min with 0.5% crystal violet. All samples were photographed, and the number of visible colonies was counted.
Kaplan-Meier data analysis
All of the clinical data and Tier 3 RNASeqV2 mRNA expression data were downloaded from The Cancer Genome Atlas (https://tcga-data.nci.nih.gov/tcga/). Patients with a follow-up time or time to death greater than 0 days were kept for analysis. For each gene, all samples were divided into two groups based on the median expression value of the respective gene. Kaplan-Meier analysis was performed to test the significance between both groups. Cox proportional hazards regression was also performed with the coxph function from the R survival library. Hazard ratios with 95% confidence intervals were obtained.
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Cellular Physiology and Biochemistry Immunofluorescence assay CAL-27 cells were seeded on cover slips with different treatments. After 48 h, the cells were fixed and incubated with an anti-Ki-67 antibody (Cell Signaling Technology) for 1 h and incubated with Alexa-488 at room temperature for 20 min. The cells were counterstained with DAPI for nuclei. All cover slips were mounted using ProLong® Diamond Antifade Mountant (Thermo Fisher Scientific).
Tumor xenograft nude mouse model CAL-27 cells were transfected with either miR-182-5p-inhibitor or miR-NC. CAL-27 cells (5.0 × 10 6 cells) were injected subcutaneously into the back of 6-week-old male BALB/c nude mice (Vital River Laboratory Animal Technology, Beijing, China) (n = 6/group) to generate OSCC tumors. Tumor volumes were measured using the formula:
, where L and S are the long and short diameter, respectively. A tumor growth curve was constructed twice a week to determine the effects of the miR-182-5p-inhibitor and miR-NC on tumor growth. After 21 days, the mice were sacrificed. Tumors in each group were dissected and weighed. Total protein and RNA were extracted from the tumors for western blotting and quantitative real-time PCR (qRT-PCR).
Statistical analysis
Data are presented as the mean ± standard deviation (SD). Comparisons between two groups were performed using the t-test, while analysis of variance was used for comparisons involving more than two groups and among groups. Pearson correlation analysis was also performed. P-values less than 0.05 were determined to be significant. All statistical calculations were conducted using SPSS software version 19 (SPSS, Inc., Chicago, IL).
Results
miR-182-5p expression in OSCC
OSCC tissue samples were examined to determine the expression levels of miR-182-5p. miR-182-5p expression was up-regulated in tumor samples compared with healthy adjacent tissue (Fig. 1A) . Similarly, miR-182-5p expression was also found to be increased in OSCC cell lines (SCC-4, CAL-27, Tca8113, UM-1, and OSC-4) in contrast to hNOK bronchial epithelial cells (Fig. 1B) .
miR-182-5p regulates OSCC cell viability
The CCK-8 assay was used to determine the viability of CAL-27 cells transfected with either miR-182-5p-mimic or -inhibitor. CAL-27 cellular proliferation was inhibited when miR-182-5p was knocked down. On the other hand, miR-182-5p over-expression increased CAL-27 cell viability ( Fig. 2A) . Cell colony formation assays indicated similar patterns in Figure 1 . transfected CAL-27 colonies. Colony formation was inhibited in the miR-182-5p-inhibitor group, but was promoted in the miR-182-5p-mimic group (Fig. 2B) . Likewise, the Ki-67 assay revealed a decrease in CAL-27 cell proliferation in the miR-182-5p-inhibitor group (Fig. 2C) . Interpreted together, these data indicate that miR-182-5p is a negative regulator of CAL-27 cell proliferation. 
CAMK2N1 is a direct target of miR-182-5p in CAL-27 cells
We attempted to identify genes targeted by miR-182-5p in CAL-27 cells. CAMK2N1 expression was examined in both OSCC patients and cell lines (Fig. 3A, B) . Overall survival times (as determined by Kaplan-Meier analysis) were markedly longer in patients that had elevated CAMK2N1 expression compared with patients with negative or low CAMK2N1 expression (Fig. 3C) . Additionally, we found that CAMK2N1 protein and mRNA levels were up-regulated in miR-182-5p-inhibitor cells in contrast to miR-NC cells (Fig. 3D, E) . Moreover, cell transfection with the miR-182-5p-mimic down-regulated CAMK2N1 mRNA and protein levels. Subsequent bioinformatics analysis (using www.targetscan.org) revealed that there was a putative binding site for miR-182-5p in the 3′-untranslated region (3′-UTR) of CAMK2N1 mRNA (Fig. 3F) . We also found that co-transfection with miR-182-5p-mimics/ CAMK2N1-WT significantly reduced luciferase activity, while co-transfection with miR-182-5p-inhibitor/CAMK2N1-WT increased luciferase activity (Fig. 3G) . On the basis of these findings, we are able to conclude that miR-182-5p directly targets CAMK2N1.
CAMK2N1 regulates CAL-27 cell viability
The CCK-8 assay revealed that the viability of CAL-27 cells was increased in cells transfected with CAMK2N1-siRNA and decreased in cells over-expressing CAMK2N1 (Fig. 4A ) compared with the control group. The colony formation assay also showed that CAMK2N1-siRNA promoted cell proliferation, while over-expressing CAMK2N1 inhibited cell proliferation (Fig. 4B) . Likewise, the Ki-67 assay revealed an increase in CAL-27 cell proliferation in the CAMK2N1-siRNA group, but this was inhibited by CAMK2N1 overexpression (Fig. 4C) . Interpreted together, these data indicate that CAMK2N1 is an important regulator of CAL-27 cell proliferation.
Co-transfection of CAL-27 cells with miR-182-5p-inhibitor/CAMK2N1-siRNA restores cell growth
To confirm if miR-182-5p targeting of CAMK2N1 promoted CAL-27 cell proliferation, CAL-27 cells were co-transfected with CAMK2N1-siRNA and miR-182-5p-inhibitor. We first quantified miR-182-5p and CAMK2N1 mRNA and protein levels (Fig. 5A, B) . The CCK-8 assay validated that co-transfection with CAMK2N1-siRNA/miR-182-5p-inhibitor restored the regenerative capability of CAL-27 cells (Fig. 5C) . Colony formation and Ki-67 assays also confirmed that CAL-27 cell viability was restored by co-transfection with miR-182-5p-inhibitor/CAMK2N1-siRNA (Fig. 5D, E) . Our findings indicate that miR-182-5p-targeted CAMK2N1 is responsible for regulating the growth of CAL-27 cells. miR-182-5p expression inhibits AKT, ERK1/2, and NF-κB activation miR-182-5p-mimic-transfected CAL-27 cells were used for protein quantification. Western blot analysis showed that the phosphorylation of AKT, ERK1/2, and NF-κB was enhanced in CAL-27 cells treated with miR-182-5p-mimic (Fig. 6A-C) , and diminished in cells transfected with miR-182-5p-inhibitor (Fig. 6D, E) . 
miR-182-5p downregulation inhibits tumor growth in vivo
To investigate further how miR-182-5p modulates tumor proliferation in vivo, we employed the use of a xenograft model of human CAL-27 cell transplantation in nude mice. Mice injected with CAL-27 cells transfected with miR-182-5p-inhibitor demonstrated significant decreases in tumor size and weight compared with the miR-NC group (Fig.  7A-C) . Meanwhile, immunoblotting assays indicated that CAMK2N1 mRNA was expressed at a higher level in tumor tissues from mice in the miR-182-5p-inhibitor group compared with tissues from the mice in the miR-NC group (Fig. 7D) . Similar trends were observed for CAMK2N1 protein expression (Fig. 7E ). In conclusion, these findings indicate that miR-182-5p operates as a tumor suppressor in OSCC. 
Discussion
OSCC is a highly prevalent cancer worldwide, especially in developing regions such as Southeast China [16] . Current research has been looking into potential biomarkers and new therapeutic agents for OSCC. Our study provides evidence that miR-182-5p augments OSCC cell proliferation by modulating CAMK2N1 expression. We demonstrated that miR-182-5p dysregulation is a central factor in OSCC pathogenesis through its proliferation-enhancing effects.
miRNAs are RNA molecules of approximately 22 nucleotides in length that bind to the 3′-UTR region of their respective target genes and exert their influence on gene expression 
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by either inhibiting protein translation or degrading mRNA. miRNAs are known to be an integral component of cancer development [17] [18] [19] . Several studies have highlighted the role of miR-182-5p in the development of different cancers [13, 14] . In glioblastoma, miR-182-5p targets protein phosphatase 1 regulatory inhibitor subunit 1C [20] . miR-182-5p promotes the progression of hepatocellular carcinoma by repressing FOXO3a expression [21] . By down-regulating RAB27A expression, miR-182-5p improves the migration, mitosis, viability, and invasion capabilities of human gastric cancer cells [22] . Inhibiting miR-182-5p by regulating CASP9 expression confers pro-apoptotic and anti-proliferative effects in human breast cancer [23] . Activated STAT3 induces miR-182-5p expression, which has been found to enhance the growth of glioma tumors [24] . Our study is the first to outline a role for miR-182-5p in the proliferation of OSCC cells. The CAMK2N1 gene, a calcium/calmodulin-dependent protein kinase II inhibitor, is a known potent modulator of tumorigenesis and subsequent tumor growth [15] . CAMK2N1 expression may have a tumor suppressing role in certain cancers, and its dysregulation has been linked to tumorigenesis [25] . CAMK2N1 halts the progression of prostate cancer by interacting with androgen receptor signaling pathways [25] . Furthermore, in castrationresistant prostate cancer, CAMK2N1 may have a tumor suppressive role [26] . Nevertheless, data regarding the interactions of miRNAs with CAMK2N1 are scarce. In this study, CAMK2N1 was discovered to be directly downstream from miR-182-5p, as evidenced by luciferase assay data. Dysfunctional miR-182-5p expression was rescued by CAMK2N1 re-expression. Taken together, our findings indicate that CAMK2N1 is regulated by miR-182-5p to drive the proliferation of OSCC cells.
Conclusion
In summary, miR-182-5p plays a vital role in controlling OSCC cell apoptosis and proliferation by regulating CAMK2N1 expression, which was found to be reduced in OSCC. Down-regulation of miR-182-5p expression attenuated tumor growth, cell survival, and proliferation in vivo through the regulation of the AKT/ERK1/2/NF-κB signaling pathways. With these findings, we gain a better understanding of the molecular mechanisms underlying the progression of OSCC and propose miR-182-5p as a future biomarker and novel therapeutic target for OSCC.
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